BACKGROUND: This study examines the effect of weight loss following laparoscopic Roux-en-Y gastric bypass (RYGBP) for morbid obesity on prescription drug costs in patients over the age of 54. METHODS: 78 patients aged 55 to 75 who met the inclusion criteria were identified in a database of 1,060 morbidly obese patients undergoing LRYGBP between March 2001 and March 2003. All prescription drugs and dosages were recorded preoperatively and postoperatively at 6 months, 1 year, and yearly thereafter. Drug history was obtained from the patient and verified by records from referring physicians' offices. The cost of a 30-day supply of each drug was obtained from 3 retail sources and averaged. RESULTS: The average pre-LRYGBP cost of prescription drugs was $368.65 per month per patient. The average annualized cost at 6 months after LRYGBP was $119.10 per month (down 68%), at 1 year $118.67 (down 68%) and at 2 years $104.68 per month (down 72%). CONCLUSIONS: Weight loss resulting from LRYGBP significantly reduces obesity-related morbidities, resulting in a substantial reduction in medication needs in patients over the age of 54. The projected cost savings realized in the 78 patients in this study amounts to approximately $240,566.04 annually.
BACKGROUND: This study examines the effect of weight loss following laparoscopic Roux-en-Y gastric bypass (RYGBP) for morbid obesity on prescription drug costs in patients over the age of 54. METHODS: 78 patients aged 55 to 75 who met the inclusion criteria were identified in a database of 1,060 morbidly obesepatients undergoing LRYGBP between March 2001 and March 2003. All prescription drugs and dosages were recorded preoperatively and postoperatively at 6 months, 1 year, and yearly thereafter. Drug history was obtained from the patient and verified by records from referring physicians' offices. The cost of a 30-day supply of each drug was obtained from 3 retail sources and averaged. RESULTS: The average pre-LRYGBP cost of prescription drugs was $368.65 per month per patient. The average annualized cost at 6 months after LRYGBP was $119.10 per month (down 68%), at 1 year $118.67 (down 68%) and at 2 years $104.68 per month (down 72%). CONCLUSIONS:Weight loss resulting from LRYGBP significantly reduces obesity-related morbidities, resulting in a substantial reduction in medication needs in patients over the age of 54. The projected cost savings realized in the 78 patients in this study amounts to approximately $240,566.04 annually.
Authors: Simon C Hawkins; Alan Osborne; Ian G Finlay; Swethan Alagaratnam; Janet R Edmond; Richard Welbourn Journal: Obes Surg Date: 2007-04 Impact factor: 4.129
Authors: Laura N McEwen; Renuka B Coelho; Lauren M Baumann; Dori Bilik; Betsy Nota-Kirby; William H Herman Journal: Obes Surg Date: 2010-07 Impact factor: 4.129
Authors: Amy L Kennedy; Tracy Nelson; Stefan Pettine; Benjamin F Miller; Karyn L Hamilton; Elise L Donovan Journal: Obes Surg Date: 2014-05 Impact factor: 4.129
Authors: David Arterburn; Daniel P Schauer; Ruth E Wise; Keith S Gersin; David R Fischer; Calvin A Selwyn; Anne Erisman; Joel Tsevat Journal: Obes Surg Date: 2008-08-13 Impact factor: 4.129
Authors: Edward C F Lam; Daniel Murariu; Edwin Takahashi; Chan W Park; Racquel S Bueno; Cedric S F Lorenzo Journal: Hawaii J Med Public Health Date: 2013-02